Paradigm suspension deepens as creditors assess uncertain recovery
Paradigm Biopharmaceuticals has entered voluntary administration after its pivotal Phase 3 trial produced an interim efficacy result below the threshold required for continuation. The company’s securities will remain suspended while administrators assess its viability, liabilities and possible restructuring options.
- FTI Consulting appointed to control Paradigm’s business and assets
- Phase 3 PARA_OA_012 trial will not proceed as planned
- Potential deed of company arrangement remains subject to creditor approval
- ASX says Paradigm’s financial condition is inadequate for continued quotation
- Clinical data review is conditional on funding and administrators’ assessment
Administrators Take Control After Trial Setback
Paradigm Biopharmaceuticals Limited (ASX:PAR) has moved into voluntary administration after the interim efficacy result from its Phase 3 PARA_OA_012 trial fell below the pre-specified threshold required for the study to continue as planned. The company appointed Christopher Pattinson and Hayden White of FTI Consulting as joint and several administrators, effective 29 September.
The appointment transfers control of Paradigm’s business, operations, property and assets to the administrators. The board’s powers are suspended, leaving FTI Consulting to independently examine the company’s financial position, ongoing viability and potential restructuring paths.
Proposed Restructuring Puts Creditors First
Paradigm says it intends to work with Obsidian Global GP, LLC and other stakeholders on a possible deed of company arrangement, or DOCA. The proposed mechanism is intended to restructure liabilities while preserving the company’s intellectual property and available clinical data, but no DOCA has been approved, and there is no certainty one will be proposed, accepted or implemented.
That uncertainty is the central issue for shareholders. Any restructuring proposal would require creditor approval, and the company has expressly warned that the eventual outcome for both creditors and shareholders remains uncertain. The board’s stated concern is a mismatch between liabilities payable in the short term and the longer-term value it ascribes to its intellectual property portfolio.
ASX Suspension Continues Under Listing Rule 12.2
ASX has continued the suspension of Paradigm’s securities under Listing Rule 17.3, saying the company’s financial condition is not adequate to warrant continued quotation and that Paradigm is therefore in breach of Listing Rule 12.2. Trading will not resume simply because the administration reaches a new stage: ASX must first be satisfied that the listing rules are met and that reinstatement is appropriate.
Paradigm expects the combined clinical review and restructuring process to take at least eight weeks from the administrators’ appointment, although that estimate may extend. The company’s available clinical data may still be analysed, including the potential effect of missing data on the interim result, but that work is conditional on the administrators’ assessment and available resources. The next material test is the first statutory meeting of creditors, expected on 9 October, followed by any proposal that can secure creditor support.
Bottom Line?
Paradigm’s future now depends less on the next clinical milestone than on whether creditors and administrators can preserve enough value to support a viable restructuring.
Questions in the middle?
- Will the administrators recommend a DOCA, liquidation or another restructuring outcome?
- Can the available PARA_OA_012 data support a credible development path after missing the continuation threshold?
- What conditions, if any, would ASX require before considering reinstatement of Paradigm’s securities?
